Powder: -20°C for 3 years | In solvent: -80°C for 1 year
LTF4 is a cysteinyl-leukotriene produced in vitro, but not reported to date in vivo. It is formed by the incubation of LTE4 with γ-glutamyl transpeptidase and glutathione. LTF4 is a weak agonist in its ability to contract vascular smooth muscle. [1] The rank order of potency of the cysteinyl-leukotrienes to contract vascular smooth muscle is LTD4 < LTC4 < LTE4 << LTF4. [1] [2]
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 μg | ¥ 2,320 | 35日内发货 | ||
50 μg | ¥ 4,390 | 35日内发货 | ||
100 μg | ¥ 8,290 | 35日内发货 |
产品描述 | LTF4 is a cysteinyl-leukotriene produced in vitro, but not reported to date in vivo. It is formed by the incubation of LTE4 with γ-glutamyl transpeptidase and glutathione. LTF4 is a weak agonist in its ability to contract vascular smooth muscle. [1] The rank order of potency of the cysteinyl-leukotrienes to contract vascular smooth muscle is LTD4 > LTC4 > LTE4 >> LTF4. [1] [2] |
别名 | LTF4 |
分子量 | 568.72 |
分子式 | C28H44N2O8S |
CAS No. | 83851-42-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMF: >50 mg/mL (per Ramki Iyer)
Ethanol: >50 mg/mL (per Ramki Iyer)
DMSO: >50 mg/mL (per Ramki Iyer)
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Leukotriene F4 83851-42-7 LTF4 LTF-4 LTF 4 Leukotriene F-4 Inhibitor inhibitor inhibit